{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T01:26:22Z","timestamp":1772846782637,"version":"3.50.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2010,6,28]],"date-time":"2010-06-28T00:00:00Z","timestamp":1277683200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1007\/s12325-010-0039-0","type":"journal-article","created":{"date-parts":[[2010,7,21]],"date-time":"2010-07-21T07:50:35Z","timestamp":1279698635000},"page":"426-443","source":"Crossref","is-referenced-by-count":34,"title":["Urapidil, a dual-acting antihypertensive agent: Current usage considerations"],"prefix":"10.1007","volume":"27","author":[{"given":"Jan","family":"Buch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,28]]},"reference":[{"key":"39_CR1","volume-title":"Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors","year":"2004","unstructured":"Ezzati M, Lopez A, Rodgers A, Vander Hoorn S, Murray CJL, eds. Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Geneva: World Health Organization; 2004."},{"key":"39_CR2","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1056\/NEJMsa0903829","volume":"361","author":"A.V. Chobanian","year":"2009","unstructured":"Chobanian AV. Shattuck Lecture. The hypertension paradox - more uncontrolled disease despite improved therapy. N Engl J Med. 2009;361:878\u2013887.","journal-title":"N Engl J Med"},{"key":"39_CR3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/01.HYP.0000103630.72812.10","volume":"43","author":"K. Wolf-Maier","year":"2004","unstructured":"Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43:10\u201317.","journal-title":"Hypertension"},{"key":"39_CR4","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/jhh.2009.76","volume":"24","author":"M. Thoenes","year":"2010","unstructured":"Thoenes M, Neuberger HR, Volpe M, Khan BV, Kirch W, B\u00f6hm M. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens. 2010;24:536\u2013544.","journal-title":"J Hum Hypertens"},{"key":"39_CR5","first-page":"13","volume":"13","author":"R.L. Antikainen","year":"2006","unstructured":"Antikainen RL, Moltchanov VA, Chukwuma C Sr, et al. WHO MONICA Project. Trends in the prevalence, awareness, treatment and control of hypertension: the WHO MONICA roject. Eur J Cardiovasc Prev Rehabil. 2006;13:13\u201329.","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"39_CR6","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1161\/HYPERTENSIONAHA.108.125617","volume":"53","author":"E. Falaschetti","year":"2009","unstructured":"Falaschetti E, Chaudhury M, Mindell J, Poulter N. Continued improvement in hypertension management in England: results from the Health Survey for England 2006. Hypertension. 2009;53:480\u2013486.","journal-title":"Hypertension"},{"key":"39_CR7","first-page":"1462","volume":"28","author":"G. Mancia","year":"2007","unstructured":"Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462\u20131536.","journal-title":"Eur Heart J"},{"key":"39_CR8","doi-asserted-by":"crossref","unstructured":"Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:(doi: 10.1136\/bmj.b1665).","DOI":"10.1136\/bmj.b1665"},{"key":"39_CR9","first-page":"217","volume":"110","author":"D. Bacquer De","year":"2006","unstructured":"De Bacquer D, De Backer G. The prevalence of concomitant hypertension and hypercholesterolaemia in the general population. Int J Hypertens. 2006;110:217\u2013223.","journal-title":"Int J Hypertens"},{"key":"39_CR10","first-page":"CD004643","volume":"4","author":"B.S. Heran","year":"2009","unstructured":"Heran BS, Galm BP, Wright JM. Blood pressure lowering efficacy of alpha blockers for primary hypertension. Cochrane Database Syst Rev. 2009;4:CD004643.","journal-title":"Cochrane Database Syst Rev"},{"key":"39_CR11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1742-1241.2000.tb11839.x","volume":"54","author":"R.M. Zusman","year":"2000","unstructured":"Zusman RM. The role of alpha 1-blockers in combination therapy for hypertension. Int J Clin Pract. 2000;54:36\u201340.","journal-title":"Int J Clin Pract"},{"issue":"suppl.4","key":"39_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199000404-00003","volume":"40","author":"P.A. Zwieten van","year":"1990","unstructured":"van Zwieten PA, Blauw GJ, van Brummelen P. Pharmacological profile of antihypertensive drugs with serotonin receptor and alpha-adrenoceptor activity. Drugs. 1990;40(suppl. 4):1\u20138.","journal-title":"Drugs"},{"key":"39_CR13","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2165\/00003495-199856050-00016","volume":"56","author":"M. Dooley","year":"1998","unstructured":"Dooley M, Goa KL. Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998;56:929\u2013955.","journal-title":"Drugs"},{"key":"39_CR14","first-page":"38","volume":"3","author":"A. Zanchetti","year":"1995","unstructured":"Zanchetti A. Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group. Blood Press Suppl. 1995;3:38\u201346.","journal-title":"Blood Press Suppl"},{"key":"39_CR15","first-page":"274","volume":"50","author":"K. Mizuno","year":"1991","unstructured":"Mizuno K, Fukuchi S. Antihypertensive effectiveness of urapidil alone and in combination with nifedipine in mild to moderate essential hypertension. Curr Ther Res. 1991;50:274\u2013281.","journal-title":"Curr Ther Res"},{"issue":"suppl.4","key":"39_CR16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2165\/00003495-199000404-00017","volume":"40","author":"R. Fariello","year":"1990","unstructured":"Fariello R, Dal Palu C, Pessina A, et al. Antihypertensive efficacy of urapidil versus hydrochlorothiazide alone in patients with mild to moderate essential hypertension and of their combination in nonresponders to monotherapy. Drugs. 1990;40(suppl. 4):60\u201362.","journal-title":"Drugs"},{"issue":"suppl.6","key":"39_CR17","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2165\/00003495-198800356-00021","volume":"35","author":"Y. Kaneko","year":"1988","unstructured":"Kaneko Y. Double-blind comparison of urapidil and prazosin in the treatment of patients with essential hypertension. Drugs. 1988;35(suppl. 6):156\u2013163.","journal-title":"Drugs"},{"key":"39_CR18","first-page":"S37","volume":"6","author":"T. Takeda","year":"1988","unstructured":"Takeda T, Kaneko Y, Shionoiri H, et al. Urapidil in patients with severe hypertension and in long-term treatment. J Hypertens Suppl. 1988;6:S37\u201342.","journal-title":"J Hypertens Suppl"},{"key":"39_CR19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.hjh.0000194119.42722.21","volume":"24","author":"G. Mancia","year":"2006","unstructured":"Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006;24:3\u201310.","journal-title":"J Hypertens"},{"key":"39_CR20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","volume":"369","author":"W.J. Elliott","year":"2007","unstructured":"Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network metaanalysis. Lancet. 2007;369:201\u2013207.","journal-title":"Lancet"},{"key":"39_CR21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/eurheartj\/13.suppl_A.65","volume":"13suppl.A","author":"R. Fariello","year":"1992","unstructured":"Fariello R, Boni E, Corda L, Zaninelli A, Noseda A, Spinazzi A. Influence of a new multifactorial antihypertensive on blood pressure and metabolic profile in essential hypertension associated with non-insulin-dependent diabetes mellitus. Eur Heart J. 1992;13(suppl. A):65\u201369.","journal-title":"Eur Heart J"},{"key":"39_CR22","first-page":"123","volume":"10","author":"S. Oren","year":"1996","unstructured":"Oren S, Turkot S, Paran E, Flandra O, Slezak L, Hof B. Efficacy and tolerability of slow release urapidil (ebrantil) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM). J Hum Hypertens. 1996;10:123\u2013127.","journal-title":"J Hum Hypertens"},{"key":"39_CR23","first-page":"870","volume":"51","author":"Y. Goto","year":"1992","unstructured":"Goto Y. Effects of sustained-release urapidil on essential hypertension and hyperlipidaemia: a multicenter clinical trial. Curr Ther Res. 1992;51:870\u2013876.","journal-title":"Curr Ther Res"},{"key":"39_CR24","first-page":"39","volume":"4","author":"L.A. Ferrara","year":"1994","unstructured":"Ferrara LA, Leonetti G, Fogari R, Mazzola C, Mancini M, Zanchetti A. Urapidil in hypercholesterolemic hypertensive patients. Blood Press Suppl. 1994;4:39\u201344.","journal-title":"Blood Press Suppl"},{"key":"39_CR25","first-page":"61","volume":"196","author":"J.W. Pattenier","year":"1992","unstructured":"Pattenier JW, von Heusinger FC. Effect of urapidil treatment on lipid metabolism in patients with hypertension. Royal Soc Med Int Congr Symp. 1992:196:61\u201367.","journal-title":"Royal Soc Med Int Congr Symp"},{"key":"39_CR26","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/01.HYP.7.6.963","volume":"7","author":"A. Gerber","year":"1985","unstructured":"Gerber A, Weidmann P, Marone C, Uehlinger D, Riesen W. Cardiovascular and metabolic profile during intervention with urapidil in humans. Hypertension. 1985;7:963\u2013971.","journal-title":"Hypertension"},{"key":"39_CR27","first-page":"2","volume":"5","author":"K. Held","year":"1985","unstructured":"Held K, Cremer P, Hundertmark E, Seidel D. Effects of long-term antihypertensive therapy with Urapidil (EbrantilR) on lipometabolism. Hochdruck. 1985;5:2.","journal-title":"Hochdruck"},{"key":"39_CR28","first-page":"651","volume":"106","author":"H. Liebau","year":"1988","unstructured":"Liebau H, Wurst W, Harder I, Solleder P. Metabolically neutral therapy of hypertension. An open, multicenter, prospective long-term study of the tolerance, safety and effectiveness of urapidil [in German]. Fortschr Med. 1988;106:651\u2013654.","journal-title":"Fortschr Med"},{"key":"39_CR29","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0026-0495(96)90239-5","volume":"45","author":"A. Haenni","year":"1996","unstructured":"Haenni A, Lithell H. Urapidil treatment decreases plasma fibrinogen concentration in essential hypertension. Metabolism. 1996;45:1221\u20131229.","journal-title":"Metabolism"},{"key":"39_CR30","doi-asserted-by":"crossref","first-page":"956","DOI":"10.7326\/0003-4819-118-12-199306150-00008","volume":"118","author":"E. Ernst","year":"1993","unstructured":"Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993;118:956\u2013963.","journal-title":"Ann Intern Med"},{"key":"39_CR31","first-page":"1799","volume":"294","author":"J. Danesh","year":"2005","unstructured":"Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294:1799\u20131809.","journal-title":"JAMA"},{"key":"39_CR32","first-page":"274","volume":"32","author":"K. Sebekova","year":"1990","unstructured":"Sebekova K, Fedelesova V, Blazicek P, Dzurik R. Acute effect of urapidil on peripheral serotonin metabolism. Cor Vasa. 1990;32:274\u2013281.","journal-title":"Cor Vasa"},{"issue":"suppl.4","key":"39_CR33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2165\/00003495-199000404-00013","volume":"40","author":"C.C. Smith","year":"1990","unstructured":"Smith CC, Betteridge DJ, Prichard BN. Platelet in vitro responses to urapidil and prazosin. Drugs. 1990;40(suppl. 4):48\u201351.","journal-title":"Drugs"},{"key":"39_CR34","first-page":"303","volume":"28","author":"J. Storck","year":"1990","unstructured":"Storck J, Ochs JG, Kirsten R. Effects of urapidil on 5-hydroxytryptamine induced platelet aggregation and on 14C-5-hydroxytryptamine uptake in platelets. Int J Clin Pharmacol Ther Toxicol. 1990;28:303\u2013308.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"39_CR35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000282443","volume":"50","author":"K. Kawabe","year":"1993","unstructured":"Kawabe K, Tsuchida S, Shimazaki J, Morita T, Yasuda K, Kageyama S. Effect on urapidil on benign prostatic hypertrophy: a multicenter, double-blind study. Urol Int. 1993;50:27\u201332.","journal-title":"Urol Int"},{"key":"39_CR36","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0022-5347(01)65723-9","volume":"156","author":"K. Yasuda","year":"1996","unstructured":"Yasuda K, Yamanishi T, Kawabe K, Ohshima H, Morita T. The effect of urapidil on neurogenic bladder: a placebo controlled double-blind study. J Urol. 1996;156:1125\u20131130.","journal-title":"J Urol"},{"key":"39_CR37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000019818","volume":"35","author":"T. Yamanishi","year":"1999","unstructured":"Yamanishi T, Yasuda K, Homma Y, Kawabe K, Morita T. A multicenter placebo-controlled, double-blind trial of urapidil, an alpha-blocker, on neurogenic bladder dysfunction. Eur Urol. 1999;35:45\u201351.","journal-title":"Eur Urol"},{"key":"39_CR38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1442-2042.2004.00753.x","volume":"11","author":"T. Yamanishi","year":"2004","unstructured":"Yamanishi T, Yasuda K, Kamai T, et al. Combination of a cholinergic drug and an alpha-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor. Int J Urol. 2004;11:88\u201396.","journal-title":"Int J Urol"},{"key":"39_CR39","first-page":"622","volume":"41","author":"Y. Ikeda","year":"1992","unstructured":"Ikeda Y, Takagi N, Takeda K. Clinical evaluation of urapidil in hypertensive patients with renal failure. Shinyaku to Rinsho. 1992;41:622\u2013631.","journal-title":"Shinyaku to Rinsho"},{"issue":"suppl.6","key":"39_CR40","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2165\/00003495-198800356-00010","volume":"35","author":"P.W. Leeuw de","year":"1988","unstructured":"de Leeuw PW, van Es PN, de Bruyn HA, Birkenh\u00e4ger WH. Renal haemodynamic and neurohumoral responses to urapidil in hypertensive man. Drugs. 1988;35(suppl. 6):74\u201377.","journal-title":"Drugs"},{"key":"39_CR41","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1097\/00004872-200018070-00019","volume":"18","author":"A.T. Lavrijssen","year":"2000","unstructured":"Lavrijssen AT, Kroon AA, Fuss-Lejeune M, Schiffers PM, de Leeuw PW. Renal haemodynamics and sodium excretory capacity during urapidil treatment in patients with essential hypertension. J Hypertens. 2000;18:963\u2013969.","journal-title":"J Hypertens"},{"key":"39_CR42","first-page":"651","volume":"106","author":"H. Liebau","year":"1988","unstructured":"Liebau H, Wurst W, Harder I, Solleder P. Metabolically neutral therapy of hypertension. An open, multicenter, prospective long-term study of the tolerance, safety and effectiveness of urapidil. Fortschr Med. 1988;106:651\u2013654.","journal-title":"Fortschr Med"},{"key":"39_CR43","first-page":"325","volume":"108","author":"H. Liebau","year":"1990","unstructured":"Liebau H, Solleder P, Harder I, Wurst W. Long-term antihypertensive therapy with urapidil. A 3-year open, multicenter trial of tolerance, safety and effectiveness. Fortschr Med. 1990;108:325\u2013328.","journal-title":"Fortschr Med"},{"key":"39_CR44","first-page":"215","volume":"22","author":"R. Haerlin","year":"1985","unstructured":"Haerlin R. Treatment of primary and secondary hypertension. Long-term use of urapidil (Ebrantil\u00ae). Clinical Trials J. 1985;22:215\u2013225.","journal-title":"Clinical Trials J"},{"key":"39_CR45","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1046\/j.1525-1497.2002.20389.x","volume":"17","author":"D. Cherney","year":"2002","unstructured":"Cherney D, Straus S. Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature. J Gen Intern Med. 2002;17:937\u2013945.","journal-title":"J Gen Intern Med"},{"key":"39_CR46","first-page":"CD003653","volume":"1","author":"M.I. Perez","year":"2008","unstructured":"Perez MI, Musini VM. Pharmacological interventions for hypertensive emergencies. Cochrane Database Syst Rev. 2008;1:CD003653.","journal-title":"Cochrane Database Syst Rev"},{"key":"39_CR47","volume-title":"Poussees hypertensives de l\u2019adulte: elevation tensionnelle sans souffrance viscerale immediate et urgences hypertensives","author":"Agence Fran\u00e7aise de S\u00e9curit\u00e9 Sanitaire Des Produits de Sant\u00e9","year":"2002","unstructured":"Agence Fran\u00e7aise de S\u00e9curit\u00e9 Sanitaire Des Produits de Sant\u00e9 (AFSSAPS). Poussees hypertensives de l\u2019adulte: elevation tensionnelle sans souffrance viscerale immediate et urgences hypertensives [in French]. Agence Fran\u00e7aise de S\u00e9curit\u00e9 Sanitaire Des Produits de Sant\u00e9, Saint Denis, France, May 2002. Available at www.afssaps.fr\/var\/afssaps_site\/storage\/original\/application\/460262f69aa6b448962c08cba7d8be4f.pdf . Accessed May 24, 2010."},{"key":"39_CR48","first-page":"7","volume":"11","author":"J. Slany","year":"2007","unstructured":"Slany J, Magometschnigg D, Mayer G, et al. Klassifikation, Diagnostik und Therapie der Hypertonie 2007 - Empfehlungen der \u00d6sterreichischen Gesellschaft f\u00fcr Hypertensiologie [in German]. J Hypertonie. 2007;11:7\u201311.","journal-title":"J Hypertonie"},{"key":"39_CR49","first-page":"624","volume":"102","author":"J. Z\u00e4hringer","year":"1984","unstructured":"Z\u00e4hringer J, Klepzig M, Greif J, Ludwig B, Strauer B. Therapy of the hypertensive crisis with urapidil. Various effects on patients with or without coronary disease. Fortschr Med. 1984;102:624\u2013628.","journal-title":"Fortschr Med"},{"key":"39_CR50","first-page":"512","volume":"94","author":"K. B\u0142aszyk","year":"1995","unstructured":"B\u0142aszyk K, Grajek S, Skorupski W, et al. Evaluation of the antihypertensive efficacy of urapidil in the treatment of hypertension emergencies [in Polish]. Pol Arch Med Wewn. 1995;94:512\u2013517.","journal-title":"Pol Arch Med Wewn"},{"key":"39_CR51","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/ajem.2001.20008","volume":"19","author":"J. Alijotas-Reig","year":"2001","unstructured":"Alijotas-Reig J, Bove-Farre I, de Cabo-Frances F, Angles-Coll R. Effectiveness and safety of prehospital urapidil for hypertensive emergencies. Am J Emerg Med. 2001;19:130\u2013133.","journal-title":"Am J Emerg Med"},{"issue":"suppl.4","key":"39_CR52","first-page":"S122","volume":"27","author":"B. Jelakovic","year":"2009","unstructured":"Jelakovic B, Grba-Bujevic M, Bosan-Kilibarda I, et al. Hypertensive crisis. Efficacy and safe of urapidil based protocol in out-of-hospital settings. J Hypertens. 2009;27(suppl. 4):S122, P11.305.","journal-title":"J Hypertens"},{"key":"39_CR53","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/0735-6757(93)90026-8","volume":"11","author":"M.M. Hirschl","year":"1993","unstructured":"Hirschl MM, Seidler D, Zeiner A, et al. Intravenous urapidil versus sublingual nifedipine in the treatment of hypertensive urgencies. Am J Emerg Med. 1993;11:653\u2013656.","journal-title":"Am J Emerg Med"},{"issue":"suppl.3","key":"39_CR54","first-page":"S143","volume":"10","author":"M.M. Hirschl","year":"1996","unstructured":"Hirschl MM, Seidler D, M\u00fcllner M, et al. Efficacy of different antihypertensive drugs in the emergency department. J Hum Hypertens. 1996;10(suppl. 3):S143\u2013146.","journal-title":"J Hum Hypertens"},{"key":"39_CR55","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s001340050426","volume":"23","author":"M.M. Hirschl","year":"1997","unstructured":"Hirschl MM, Binder M, Bur A, et al. Safety and efficacy of urapidil and sodium nitroprusside in the treatment of hypertensive emergencies. Intensive Care Med. 1997;23:885\u2013888.","journal-title":"Intensive Care Med"},{"key":"39_CR56","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.jhh.1002063","volume":"20","author":"C. Woisetschl\u00e4ger","year":"2006","unstructured":"Woisetschl\u00e4ger C, Bur A, Vlcek M, Derhaschnig U, Laggner AN, Hirschl MM. Comparison of intravenous urapidil and oral captopril in patients with hypertensive urgencies. J Hum Hypertens. 2006;20:707\u2013709.","journal-title":"J Hum Hypertens"},{"issue":"suppl.4","key":"39_CR57","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2165\/00003495-199000404-00016","volume":"40","author":"F. Sp\u00e4h","year":"1990","unstructured":"Sp\u00e4h F, Grosser KD, Thieme G. Acute haemodynamic effects of urapidil and nifedipine in hypertensive urgencies and emergencies. Drugs. 1990;40(suppl. 4):58\u201359.","journal-title":"Drugs"},{"key":"39_CR58","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/oxfordjournals.ndt.a027825","volume":"13","author":"J. Wacker","year":"1998","unstructured":"Wacker J, Werner P, Walter-Sack I, Bastert G. Treatment of hypertension in patients with preeclampsia: a prospective parallel-group study comparing dihydralazine with urapidil. Nephrol Dial Transplant. 1998;13:318\u2013325.","journal-title":"Nephrol Dial Transplant"},{"key":"39_CR59","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejogrb.2005.09.013","volume":"127","author":"J.R. Wacker","year":"2006","unstructured":"Wacker JR, Wagner BK, Briese V, et al. Antihypertensive therapy in patients with preeclampsia: A prospective randomised multicentre study comparing dihydralazine with urapidil. Eur J Obstet Gynecol Reprod Biol. 2006;127:160\u2013165.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"39_CR60","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1055\/s-2001-18226","volume":"123","author":"M. Schulz","year":"2001","unstructured":"Schulz M, Wacker J, Bastert G. Effect of Urapidil in antihypertensive therapy of preeclampsia on newborns [in German]. Zentralbl Gynakol. 2001;123:529\u2013533.","journal-title":"Zentralbl Gynakol"},{"key":"39_CR61","unstructured":"Deutsche Hochdruckliga e.V. DHLR - Deutsche Hypertonie Gesellschaft. Leitlinien zur behandlung der arteriellen hypertonie. Heidelberg, Germany, 2008. Available at: www.hochdruckliga.de . Accessed: May 24, 2010."},{"key":"39_CR62","first-page":"337","volume":"47","author":"M. Olmos","year":"2000","unstructured":"Olmos M, Vidarte MA, Ballester JA, Lasuen J, Escobar A. Efficacy of a single dose of urapidil for preventing arterial hypertension during the pre-bypass period in coronary surgery. Rev Esp Anestesiol Reanim. 2000;47:337\u2013342.","journal-title":"Rev Esp Anestesiol Reanim"},{"key":"39_CR63","first-page":"1479","volume":"31","author":"E. Gob","year":"1981","unstructured":"Gob E, Barankay A, Richter JA. Control of hypertension during cardiopulmonary bypass with urapidil and phentolamine. Arzneimittelforschung. 1981;31:1479\u20131481.","journal-title":"Arzneimittelforschung"},{"issue":"suppl.4","key":"39_CR64","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00003495-199000404-00024","volume":"40","author":"W. Hess","year":"1990","unstructured":"Hess W. Urapidil versus clonidine. Acute haemodynamic effects during control of intraoperative hypertensive episodes. Drugs. 1990;40(suppl. 4):77\u201379.","journal-title":"Drugs"},{"key":"39_CR65","first-page":"21","volume":"2","author":"W. Hess","year":"1985","unstructured":"Hess W, Schulte-Sasse U, Tarnow J, Veit S. Comparison of phentolamine and urapidil in controlling acute intra-operative hypertension in patients subjected to coronary artery bypass surgery. Eur J Anaesthesiol. 1985;2:21\u201327.","journal-title":"Eur J Anaesthesiol"},{"key":"39_CR66","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2044.1995.tb04606.x","volume":"50","author":"A. Petry","year":"1995","unstructured":"Petry A, Wulf H, Baumgartel M. The influence of ketanserin or urapidil on haemodynamics, stress response and kidney function during operations for myocardial revascularisation. Anaesthesia. 1995;50:312\u2013316.","journal-title":"Anaesthesia"},{"key":"39_CR67","first-page":"31","volume":"4","author":"J.G. Stroom van der","year":"1994","unstructured":"van der Stroom JG, Van Wezel HB, Koolen JJ, Visser CA, Van Zwieten PA. Comparison of the effects of urapidil and nitroprusside on hemodynamics and myocardial function in hypertension following cardiac surgery. Blood Press Suppl. 1994;4:31\u201338.","journal-title":"Blood Press Suppl"},{"key":"39_CR68","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1053-0770(97)90166-X","volume":"11","author":"J.G. Stroom van der","year":"1997","unstructured":"van der Stroom JG, van Wezel HB, Langemeijer JJ, et al. A randomized multicenter double-blind comparison of urapidil and ketanserin in hypertensive patients after coronary artery surgery. J Cardiothorac Vasc Anesth. 1997;11:729\u2013736.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"39_CR69","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/bja\/76.5.645","volume":"76","author":"J.G. Stroom van der","year":"1996","unstructured":"van der Stroom JG, van Wezel HB, Vergroesen I, et al. Comparison of the effects of urapidil and sodium nitroprusside on haemodynamic state, myocardial metabolism and function in patients during coronary artery surgery. Br J Anaesth. 1996;76:645\u2013651.","journal-title":"Br J Anaesth"},{"key":"39_CR70","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/bja\/64.4.493","volume":"64","author":"T. Mollhoff","year":"1990","unstructured":"Mollhoff T, Van Aken H, Mulier JP, Muller E, Lauwers P. Effects of urapidil, ketanserin and sodium nitroprusside on venous admixture and arterial oxygenation following coronary artery bypass grafting. Br J Anaesth. 1990;64:493\u2013497.","journal-title":"Br J Anaesth"},{"key":"39_CR71","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/1053-0770(93)90004-5","volume":"7","author":"J. Hemelrijck van","year":"1993","unstructured":"van Hemelrijck J, Waets P, Aken H van, Lacroix H, Nevelsteen A, Suy R. Blood pressure management during aortic surgery - Urapidil compared to isosorbide dinitrate. J Cardiothorac Vasc Anesth. 1993;7:273\u2013278.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"39_CR72","first-page":"1304","volume":"56","author":"J. Zander","year":"1984","unstructured":"Zander J, Puchstein C, Aken H van, Lawin P. Urapidil as a supplement to neuroleptanalgesia during neuroanaesthesia. Br J Anaesth. 1984;56:1304\u20131305.","journal-title":"Br J Anaesth"},{"key":"39_CR73","first-page":"224","volume":"33","author":"C. Puchstein","year":"1984","unstructured":"Puchstein C, Van Aken H, Zander J, Lawin P. The use of urapidil in the postoperative period. Anaesthesist. 1984;33:224\u2013227.","journal-title":"Anaesthesist"},{"key":"39_CR74","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/jhh.2008.172","volume":"23","author":"P. Gosse","year":"2009","unstructured":"Gosse P, Tauzin-Fin P, Sesay MB, Sautereau A, Ballanger P. Preparation for surgery of phaeochromocytoma by blockade of alpha-adrenergic receptors with urapidil: what dose? J Hum Hypertens. 2009;23:605\u2013609.","journal-title":"J Hum Hypertens"},{"key":"39_CR75","first-page":"62","volume":"3","author":"F. Spah","year":"1995","unstructured":"Spah F, Walsemann SO. Potential beneficial effects of urapidil in primary and secondary prevention of stroke. Blood Press Suppl. 1995;3:62\u201367.","journal-title":"Blood Press Suppl"},{"key":"39_CR76","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1055\/s-2007-1001037","volume":"25","author":"R. Wusten","year":"1990","unstructured":"Wusten R, Hemelrijck J, Mattheussen M, Lauvers T, Anger C, van Aken H. Der einfluss von nifidepin und urapidil auf die autoregulation der zerebralen durchbtuling in gegenwart einer intrakraniellen raumforderung [in German]. Anasth Intensivther Notfallmed. 1990;25:140\u2013145.","journal-title":"Anasth Intensivther Notfallmed"},{"key":"39_CR77","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0014-2999(91)90717-5","volume":"203","author":"J.H. Prehn","year":"1991","unstructured":"Prehn JH, Backhauss C, Karkoutly C, et al. Neuroprotective properties of 5-HT1A receptor agonists in rodent models of focal and global cerebral ischemia. Eur J Pharmacol. 1991;203:213\u2013222.","journal-title":"Eur J Pharmacol"},{"key":"39_CR78","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000072554","volume":"16","author":"European Stroke Initiative Executive Committee.","year":"2003","unstructured":"European Stroke Initiative Executive Committee. European Stroke Initiative Recommendations for Stroke Management-update 2003. Cerebrovasc Dis. 2003;16:311\u2013337.","journal-title":"Cerebrovasc Dis"},{"key":"39_CR79","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(08)70069-3","volume":"7","author":"C.S. Anderson","year":"2008","unstructured":"Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol. 2008;7:391\u2013399.","journal-title":"Lancet Neurol"},{"key":"39_CR80","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","volume":"283","author":"ALLHAT Collaborative Research Group.","year":"2000","unstructured":"ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967\u20131975.","journal-title":"JAMA"},{"key":"39_CR81","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.HYP.0000086521.95630.5A","volume":"42","author":"ALLHAT officerscoordinators for the ALLHAT Collaborative Research Group.","year":"2003","unstructured":"ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Diuretics versus alpha blockers as first-step antihypertensive therapy. Hypertension. 2003;42:239\u2013246.","journal-title":"Hypertension"},{"key":"39_CR82","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"A.V. Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206\u20131252.","journal-title":"Hypertension"},{"key":"39_CR83","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/CIRCULATIONAHA.107.737957","volume":"118","author":"N. Chapman","year":"2008","unstructured":"Chapman N, Chang CL, Dahl\u00f6f B, et al. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation. 2008;118:42\u201348.","journal-title":"Circulation"},{"key":"39_CR84","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2143\/AC.64.4.2041613","volume":"64","author":"R. Spoladore","year":"2009","unstructured":"Spoladore R, Roccaforte R, Fragasso G, et al. Safety and efficacy of doxazosin as \u201cadd-on\u201d antihypertensive therapy in mild to moderate heart failure patients. Acta Cardiol. 2009;64:485\u2013491.","journal-title":"Acta Cardiol"},{"key":"39_CR85","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/clpt.1985.10","volume":"37","author":"G.G. Belz","year":"1985","unstructured":"Belz GG, Matthews JH, Graf D, et al. Dynamic responses to intravenous urapidil and dihydralazine in normal subjects. Clin Pharmacol Ther. 1985;37:48\u201354.","journal-title":"Clin Pharmacol Ther"},{"key":"39_CR86","doi-asserted-by":"crossref","unstructured":"Kobrin I, Amodeo C, Ventura HO, Messerli FH, Frohlich ED. Immediate hemodynamic effects of urapidil in patients with essential hypertension. Am J Cardiol. 1985:722\u2013725.","DOI":"10.1016\/0002-9149(85)90144-4"},{"key":"39_CR87","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00228-006-0256-2","volume":"63","author":"K. Stoschitzky","year":"2007","unstructured":"Stoschitzky K, Stoschitzky G, Wonisch M, Brussee H. Differential effects of urapidil and doxazosin on heart rate. Eur J Clin Pharmacol. 2007;63:259\u2013262.","journal-title":"Eur J Clin Pharmacol"},{"key":"39_CR88","first-page":"21","volume":"3","author":"L. Hansson","year":"1995","unstructured":"Hansson L, Petitet A. Review of studies with urapidil in elderly hypertensives. Blood Press Suppl. 1995;3:21\u201325.","journal-title":"Blood Press Suppl"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-010-0039-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-010-0039-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-010-0039-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T06:38:10Z","timestamp":1685687890000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-010-0039-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,28]]},"references-count":88,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["39"],"URL":"https:\/\/doi.org\/10.1007\/s12325-010-0039-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,28]]}}}